Serum PAI-1 is a novel predictor for response to pegylated interferon-α-2b plus ribavirin therapy in chronic hepatitis C virus infection.
about
Metabolic alterations and hepatitis C: From bench to bedsideRelevance of baseline viral genetic heterogeneity and host factors for treatment outcome prediction in hepatitis C virus 1b-infected patientsMetabolic Dysregulation in Hepacivirus Infection of Common Marmosets (Callithrix jacchus).Link between plasminogen activator inhibitor-1 and cardiovascular risk in chronic hepatitis C after viral clearance
P2860
Serum PAI-1 is a novel predictor for response to pegylated interferon-α-2b plus ribavirin therapy in chronic hepatitis C virus infection.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Serum PAI-1 is a novel predict ...... c hepatitis C virus infection.
@en
Serum PAI-1 is a novel predict ...... c hepatitis C virus infection.
@nl
type
label
Serum PAI-1 is a novel predict ...... c hepatitis C virus infection.
@en
Serum PAI-1 is a novel predict ...... c hepatitis C virus infection.
@nl
prefLabel
Serum PAI-1 is a novel predict ...... c hepatitis C virus infection.
@en
Serum PAI-1 is a novel predict ...... c hepatitis C virus infection.
@nl
P2093
P2860
P1476
Serum PAI-1 is a novel predict ...... c hepatitis C virus infection.
@en
P2093
N Kamatani
Y Nakamura
P2860
P304
P356
10.1111/J.1365-2893.2011.01516.X
P577
2011-09-14T00:00:00Z